Wozyme D Tablet is a combination pharmaceutical formulation containing Trypsin (90mg), Bromelain (48mg), Rutoside (100mg), and Diclofenac (50mg), designed to provide effective anti-inflammatory, analgesic, and fibrinolytic effects. Trypsin and Bromelain are proteolytic enzymes that facilitate the breakdown of proteins, thereby aiding in the reduction of edema and promoting the resolution of inflammation. Rutoside, a bioflavonoid, enhances capillary strength and reduces capillary permeability, contributing to decreased swelling and improved microcirculation. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), exerts potent analgesic and anti-inflammatory actions by inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin synthesis. The synergistic action of these components makes Wozyme D Tablet effective in managing acute and chronic inflammatory conditions such as musculoskeletal injuries, postoperative inflammation, and soft tissue trauma. It is particularly useful in reducing pain, swelling, and stiffness associated with sprains, strains, and arthritis. The medication should be used under medical supervision, with caution advised in patients with known hypersensitivity to NSAIDs, bleeding disorders, or gastrointestinal ulcers. Wozyme D Tablet offers a multi-modal approach to inflammation and pain management, enhancing patient recovery and comfort.